In a pivotal phase 2 randomized trial published in the New England Journal of Medicine, orforglipron, a once-daily oral nonpeptide GLP-1RAs, demonstrated substantial and sustained weight loss among adults with obesity, with efficacy comparable to injectable agents and an acceptable safety profile [35]
Once insulin therapy is initiated, patients are infrequently titrated off this regimen, even when newer medications with additional benefits become available
Because the math behind peptide reconstitution involves converting between milligrams, micrograms, milliliters, and insulin syringe units, and one decimal place error changes everything
The Bottom Line Retatrutide could mark the next chapter in metabolic medicine, an evolution that takes the success of Ozempic and Mounjaro even further